Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance

Acquired chemotherapeutic resistance of cancer cells can result from a Darwinistic evolution process in which heterogeneity plays an important role. In order to understand the impact of genetic heterogeneity on acquired resistance and second line therapy selection in metastatic melanoma, we sequence...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Raaijmakers, Marieke I. G., Widmer, Daniel S., Narechania, Apurva, Eichhoff, Ossia, Freiberger, Sandra N., Wenzina, Judith, Cheng, Phil F., Mihic-Probst, Daniela, Desalle, Rob, Dummer, Reinhard, Levesque, Mitchell P.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363577/
https://ncbi.nlm.nih.gov/pubmed/27791198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12848
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items